Research programme: oral E-selectin inhibitors - Crescent Biopharma
Latest Information Update: 17 Jun 2025
At a glance
- Originator GlycoMimetics
- Developer Crescent Biopharma
- Class
- Mechanism of Action E-selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Cardiovascular disorders; Inflammation